Retatrutide 20mg

Contents

Use this guide as a structured review page. The same headings appear for every protocol so clients and the care team can scan the page consistently.

Quickstart Highlights

Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors[1], studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes[2][3]. With an extended half-life of approximately 6 days, this peptide enables convenient once-weekly subcutaneous dosing with a gradual titration protocol to optimize tolerability[1][4].

• Reconstitute: Add 2.0 mL bacteriostatic water → 10.0 mg/mL concentration for optimal weekly doses.
• Typical weekly range: 2–12 mg once weekly (gradual escalation over 12+ weeks).
• Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.

Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing

• Frequency: Inject once weekly subcutaneously. This schedule follows clinical trial protocols that demonstrated significant weight loss (up to 24% at 48 weeks with 12 mg weekly)[2] while minimizing gastrointestinal adverse events through gradual escalation[1][4]. Starting at 2 mg weekly (versus 4 mg) significantly reduces initial GI side effects. The 20 mg vial size with 2.0 mL reconstitution provides excellent concentration (10.0 mg/mL) for convenient measuring. For the maintenance dose (12 mg = 1.20 mL), either split into two 0.60 mL injections at different sites or reconstitute an additional vial.

Reconstitution Steps

Note: The 20 mg vial size is highly efficient for weekly protocols. Lower doses (2–8 mg) fit comfortably in a single syringe, while the maintenance dose (12 mg) requires either splitting across two injection sites or using a second vial for the remaining 0.20 mL (2 mg).

• Draw 2.0 mL bacteriostatic water with a sterile syringe.
• Inject slowly down the vial wall; avoid foaming.
• Gently swirl/roll until dissolved (do not shake vigorously).
• Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on a 12–48 week weekly protocol with gradual titration to maintenance dose.

• Peptide Vials (Retatrutide, 20 mg each): Highly efficient vial size for weekly protocols
• Peptide Vials (Retatrutide, 20 mg each): Highly efficient vial size for weekly protocols: 12 weeks (2→4→8 mg titration): 3 vials
• Peptide Vials (Retatrutide, 20 mg each): Highly efficient vial size for weekly protocols: 24 weeks (up to 12 mg): 10 vials
• Peptide Vials (Retatrutide, 20 mg each): Highly efficient vial size for weekly protocols: 48 weeks (maintenance at 12 mg): 25 vials
• Insulin Syringes (U-100, 1 mL):
• Insulin Syringes (U-100, 1 mL):: Per week: 1 syringe (once-weekly dosing)
• Insulin Syringes (U-100, 1 mL):: 12 weeks: 12 syringes
• Insulin Syringes (U-100, 1 mL):: 24 weeks: 24 syringes
• Insulin Syringes (U-100, 1 mL):: 48 weeks: 48 syringes
• Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
• Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.: 12 weeks (3 vials): 6 mL → 1 × 10 mL bottle
• Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.: 24 weeks (10 vials): 20 mL → 2 × 10 mL bottles
• Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.: 48 weeks (25 vials): 50 mL → 5 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each week.
• Alcohol Swabs: One for the vial stopper + one for the injection site each week.: Per week: 2 swabs
• Alcohol Swabs: One for the vial stopper + one for the injection site each week.: 12 weeks: 24 swabs → 1 × 100-count box
• Alcohol Swabs: One for the vial stopper + one for the injection site each week.: 24 weeks: 48 swabs → 1 × 100-count box
• Alcohol Swabs: One for the vial stopper + one for the injection site each week.: 48 weeks: 96 swabs → 1 × 100-count box

Protocol Overview

Concise summary of the once-weekly regimen based on clinical trial protocols.

• Goal: Achieve substantial weight loss (up to 24% of body weight) and improved metabolic parameters through triple receptor agonism[2][5]. Open source
• Schedule: Weekly subcutaneous injections for 12+ weeks with gradual dose escalation.
• Dose Range: 2–12 mg once weekly; clinical trials tested up to 12 mg as the maximum maintenance dose[1][3]. Open source
• Reconstitution: 2.0 mL per 20 mg vial (10.0 mg/mL) provides optimal concentration for weekly dosing with minimal waste.
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.

Dosing Protocol

Evidence-based weekly titration approach from clinical trials.

• Start: 2 mg once weekly for first 4 weeks to establish tolerability[1][4]. Open source
• Escalation: Increase to 4 mg weekly (Weeks 5–8), then 8 mg weekly (Weeks 9–12)[1]. Open source
• Maintenance: 12 mg weekly (Week 13 onward) for maximum efficacy; 8 mg weekly is an alternative maintenance dose[2]. Open source
• Frequency: Once per week (subcutaneous); consistent day/time recommended.
• Cycle Length: Minimum 12 weeks for titration; clinical trials extended to 48 weeks showing sustained weight loss[2]. Open source
• Timing: Any consistent weekly schedule; rotate injection sites each week.

Storage Instructions

Proper storage maintains peptide stability and potency.

• Lyophilized: Store at −20 °C (−4 °F) or colder for long-term preservation; protect from moisture and light[11][12]. Open source
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing; use within 2–4 weeks for maximum potency[11]. Open source
• Handling: Allow frozen vials to reach room temperature before opening to minimize condensation; never expose reconstituted solution to heat or direct sunlight.
• Aliquoting: For extended storage beyond 4 weeks, consider freezing unused aliquots; avoid repeated freeze-thaw cycles[12]. Open source

Important Notes

Practical considerations for safe and effective weekly administration.

• Weekly consistency: Choose a specific day/time for your weekly injection and maintain this schedule throughout the protocol.
• Gradual titration is essential: Starting at 2 mg weekly (versus higher doses) significantly reduces initial gastrointestinal side effects[4]. Open source
• Efficient vial size: The 20 mg vial provides excellent value, requiring only 3 vials for the first 12 weeks of titration.
• Use new sterile insulin syringes for each injection; dispose immediately in a puncture-proof sharps container[14]. Open source
• Rotate injection sites weekly (abdomen, thighs, upper arms) at least 1 inch apart to prevent local irritation or lipohypertrophy[15]. Open source
• For the 12 mg maintenance dose (1.20 mL), either split into two 0.60 mL injections at different sites or use a second vial for the remaining volume.
• Monitor for gastrointestinal side effects (nausea, diarrhea); if severe, consider extending the time at current dose before escalating.

How This Works

Retatrutide is a first-in-class triple agonist that simultaneously activates three key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon[1][5]. This triple mechanism produces synergistic effects on appetite suppression, energy expenditure, and glucose metabolism that exceed single or dual agonists.

• The GLP-1 component reduces appetite and slows gastric emptying; GIP enhances insulin secretion and may support fat metabolism; glucagon receptor activation increases energy expenditure and promotes fat oxidation[5][8]. With an extended half-life of approximately 6 days, retatrutide enables convenient once-weekly dosing while maintaining therapeutic levels[1].
• In clinical trials, participants receiving 12 mg weekly retatrutide lost an average of 24% of their body weight over 48 weeks[2]. In adults with type 2 diabetes, retatrutide (up to 12 mg weekly) achieved approximately 17% weight loss at 36 weeks alongside HbA1c reductions of approximately 2.0% compared to placebo[3]. A 2025 meta-analysis of three trials (878 participants) confirmed retatrutide achieved significantly greater weight reduction than placebo (mean difference approximately 14% of body weight) with no significant increase in overall adverse events[6][7].

Lifestyle Factors

Complementary strategies to optimize outcomes during retatrutide protocols.

• Nutrition: Adopt a balanced, protein-forward diet (1.0–1.2 g/kg body weight) to preserve lean mass during weight loss[10]. Open source
• Hydration: Maintain adequate fluid intake, especially during dose titration when GI effects are most common.
• Physical activity: Combine resistance training (2–3×/week) with moderate aerobic exercise to support metabolic adaptations and preserve muscle mass.
• Sleep & stress: Prioritize 7–9 hours of quality sleep and implement stress management techniques to support hormonal balance and adherence.
• Meal timing: Some individuals find smaller, more frequent meals help manage GI side effects during initial titration.

Potential Benefits & Side Effects

Observations from phase 2 and phase 3 clinical trials in humans.

• Substantial weight loss: Up to 24% reduction in body weight at 48 weeks with 12 mg weekly dosing[2]. Open source
• Glycemic improvement: Significant HbA1c reductions (approximately 2.0%) in adults with type 2 diabetes[3]. Open source
• Metabolic benefits: Improvements in lipid profiles, blood pressure, and cardiovascular risk markers[1][5]. Open source
• Convenient dosing: Once-weekly subcutaneous administration improves adherence compared to daily regimens[1]. Open source
• Gastrointestinal effects: Nausea, diarrhea, vomiting, and constipation are the most common adverse events; typically mild-to-moderate and diminish over time[2][4]. Open source
• Starting at 2 mg weekly (versus 4 mg) significantly reduces initial GI adverse events[4]. Open source
• Injection site reactions: Mild redness, swelling, or discomfort at injection sites may occur; rotate sites to minimize.
• Overall safety profile: Meta-analysis found no significant increase in overall adverse events compared to placebo[6][7]. Open source

Injection Technique

Subcutaneous injection guidelines based on clinical best practices and CDC recommendations[13][14].

• Wash hands thoroughly with soap and water[14]. Open source
• Clean the vial stopper with an alcohol swab and allow to air dry.
• Select injection site (abdomen, thigh, or upper arm) and clean with a fresh alcohol swab; allow to dry completely[13]. Open source
• Draw prescribed dose carefully; check for air bubbles and expel if present.
• Pinch a skinfold of approximately 1 inch between thumb and forefinger[15]. Open source
• Insert needle at a 90-degree angle (45-degree if subcutaneous fat layer is thin) into the pinched skin[13][14]. Open source
• Do not aspirate for subcutaneous injections (aspiration is not required and may increase discomfort)[13]. Open source
• Inject slowly and steadily; depress plunger completely.
• Withdraw needle straight out and apply gentle pressure with clean gauze if needed.
• Dispose of used syringe immediately in a puncture-proof sharps container; never recap needles[14]. Open source
• Return reconstituted vial to refrigerator promptly.
• Rotate injection sites weekly (at least 1 inch apart) to prevent lipohypertrophy[15]. Open source
• Monitor for excessive redness, swelling, or signs of infection at injection site.

Recommended Source

We recommend Prime Lab Peptides for high-purity Retatrutide (20 mg vials).

• Third-party tested: Each batch includes Certificate of Analysis (COA) verifying purity and composition.
• Consistent quality: ISO-aligned manufacturing and handling standards ensure reliable product integrity.
• Cold-chain integrity: Temperature-controlled shipping and storage throughout fulfillment process.
• Research-grade purity: Suitable for educational and research applications requiring high-quality peptides.
• Efficient dosing: The 20 mg vial size provides excellent value for weekly protocols with minimal waste.

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

• Do not start, stop, combine, or change a protocol based only on website content.
• Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

Reference-derived details for Retatrutide 20mg.

• Retatrutide (20 mg Vial) Open source
• New England Journal of Medicine (2023) — Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2 trial; 48-week results) View Source Open source
• JAMA Network (2023) — Retatrutide Phase 2 Obesity Trial: detailed efficacy and safety data (24% weight loss at 12 mg weekly) View Source Open source
• The Lancet (2023) — Retatrutide in type 2 diabetes: Phase 2 trial (weight loss and glycemic outcomes at 36 weeks) View Source Open source
• PubMed / NEJM (2023) — Retatrutide dosing and tolerability: starting at 2 mg vs 4 mg reduces GI adverse events View Source Open source
• Metabolites (PMC, 2025) — Retatrutide—A Game Changer in Obesity Pharmacotherapy (comprehensive review of mechanism and trials) View Source Open source
• Baylor University Medical Center Proceedings (PMC, 2025) — Efficacy and safety of retatrutide for obesity: meta-analysis of RCTs (878 participants) View Source Open source
• PubMed (2025) — Meta-analysis: Retatrutide achieves ~14% greater weight reduction vs placebo with no increase in adverse events View Source Open source
• Molecular Metabolism (2025) — Preclinical tri-agonist NN1706 (related compound): mechanism and pharmacokinetics View Source Open source
• Nature Reviews Endocrinology (2024) — Triple agonist therapies for obesity and diabetes: clinical landscape review View Source Open source
• Journal of Cachexia, Sarcopenia and Muscle (PMC) — Protein requirements during weight loss: preserving lean mass View Source Open source
• GenScript — Peptide Storage and Handling Guidelines (technical bulletin for lyophilized and reconstituted peptides) View Source Open source
• Bachem — Handling and Storage Guidelines for Peptides (technical article on stability and freeze-thaw cycles) View Source Open source
• Centers for Disease Control and Prevention (CDC) — Vaccine Administration: Subcutaneous Injection (technique, angle, and site guidance) View Source Open source
• NCBI Bookshelf — Injection Administration Best Practices (aseptic technique, sharps disposal, and safety) View Source Open source
• Pharmacologic Considerations of the Subcutaneous Route (PMC) — Subcutaneous injection technique and site rotation to prevent lipohypertrophy View Source Open source
• Prime Lab Peptides — Retatrutide (20 mg) product page (quality documentation and specifications) View Source